ClinicalTrialsFinder
RecruitingPhase 1NCT07354724

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Sponsor

Denali Therapeutics Inc.

Enrollment

32 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Late-onset Pompe Disease

Summary

This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across varous dose levels of DNL952 in participants with late-onset Pompe disease (LOPD).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

  • Body weight ≥40 kg
  • Diagnosis of LOPD
  • Upright FVC ≥ 30% of predicted normal value
  • Able to ambulate ≥ 40 meters (use of assistive devices is acceptable)
  • \[Cohorts A1-A4 only\] Have received avalglucosidase alfa or cipaglucosidase alfa at a dose of 20 mg/kg every 2 weeks for at least 12 months prior to screening
  • \[Cohorts B1-B2 only\] Must not have received any enzyme-replacement therapy for Pompe disease in the 12 months prior to screening

Exclusion Criteria4

  • Any ongoing, clinically significant, unstable, or poorly controlled neurological, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematological, immunological, allergic, or ophthalmic disease not related to Pompe disease, or other major disorders. Well-controlled conditions are permitted if investigator and Sponsor agree.
  • Wheelchair-dependent
  • Require noninvasive ventilation for an average of more than 6 hours per day while awake or any invasive ventilation. Use of noninvasive ventilation during sleep is acceptable.
  • Received an experimental gene therapy at any time or participation in any other investigational drug trial or use of investigational drug within 60 days or 5 half-lives, whichever is longer, before screening

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDNL952

Intravenous repeating dose

Locations(1)

The Lysosomal & Rare Disorders Research & Treatment Center

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07354724